Skip to main content
. 2011 Mar;178(3):1009–1020. doi: 10.1016/j.ajpath.2010.11.047

Figure 4.

Figure 4

Circulating anti-SPAG9 antibodies in CRC patients. A: Enzyme-linked immunosorbent assay analysis of sera from CRC patients of different tumor stages (I, II, III, and IV) and grades [well differentiated (WD), moderately differentiated (MD), and mucinous type], as well as 50 normal healthy donors. The horizontal line and X indicate the cutoff (mean + 2 SD of 50 normal healthy donors), with positivity above and negativity below the line. Significant difference in the seroreactivity was observed between normal healthy donors and CRC patients (P < 0.0001). B: Western blotting analysis. Lane 1: Affinity-purified recombinant SPAG9 stained with Coomassie Brilliant Blue. Serum from tumor stage I (lane 2), stage II (lane 3), stage III (lane 4), and stage IV (lane 5) showed specific immunoreactivity with recombinant SPAG9. Neutralization experiments were done by including recombinant SPAG9 (15 μg/ml) in the incubation with sera from stage I (lane 6), stage II (lane 7), stage III (lane 8), and stage IV (lane 9) patients, which resulted in loss of immunoreactivity. Western blot analysis with sera from 50 normal healthy donors revealed no reactivity (lanes 10–13).